Published in Br J Pharmacol on April 07, 2017
Hallmarks of cancer: the next generation. Cell (2011) 140.01
NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res (2015) 10.66
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
The extracellular matrix as a cell survival factor. Mol Biol Cell (1993) 6.32
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol (2015) 5.96
Protein phosphatase 1--targeted in many directions. J Cell Sci (2002) 5.59
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol (2004) 5.44
Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol (2015) 5.43
CIP2A inhibits PP2A in human malignancies. Cell (2007) 5.28
Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J (1999) 4.85
Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature (1989) 4.27
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 2.74
Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol (2007) 2.35
Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech (2003) 2.02
Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis (2009) 1.50
p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Mol Cell Biol (2001) 1.43
Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res (2003) 1.41
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev (2008) 1.37
Signalling to cancer cell invasion through PAK family kinases. Front Biosci (Landmark Ed) (2011) 1.36
Role of ADAMs in cancer formation and progression. Clin Cancer Res (2009) 1.29
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene (2012) 1.23
The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol (2001) 1.19
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res (2008) 1.13
Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene (1997) 1.06
IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res (2013) 1.02
Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J Hepatol (2007) 1.01
Ceramide-dependent PP2A regulation of TNFalpha-induced IL-8 production in respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol (2009) 0.97
Cyclosporin A inhibits Ca2+/calmodulin-dependent protein phosphatase and secretion in pancreatic acinar cells. J Biol Chem (1994) 0.96
Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol (2013) 0.96
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol (2012) 0.93
Induction of autophagy biomarker BNIP3 requires a JAK2/STAT3 and MT1-MMP signaling interplay in Concanavalin-A-activated U87 glioblastoma cells. Cell Signal (2014) 0.92
All three IkappaB isoforms and most Rel family members are stably associated with the IkappaB kinase 1/2 complex. Eur J Biochem (1999) 0.91
CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol (2012) 0.91
Activation of transforming growth factor-beta1/p38/Smad3 signaling in stromal cells requires reactive oxygen species-mediated MMP-2 activity during bone marrow damage. Stem Cells (2005) 0.91
The regulatory roles of phosphatases in cancer. Oncogene (2013) 0.91
New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol (2005) 0.89
Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells. Oncogene (2004) 0.87
Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell cultures. Kidney Int (2000) 0.87
Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A. PLoS One (2012) 0.86
Regulation of PP2A activity by Mid1 controls cranial neural crest speed and gangliogenesis. Mech Dev (2012) 0.86
TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. J Proteome Res (2013) 0.86
Okadaic acid-elicited transcriptional activation of collagenase gene expression in HT-1080 fibrosarcoma cells is mediated by JunB. Cell Growth Differ (1994) 0.86
TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One (2014) 0.85
The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. J Periodontol (2003) 0.83
Matrix metalloproteinase-9 gene polymorphism in hepatocellular carcinoma patients with hepatitis B and C viruses. Genet Mol Res (2014) 0.82
Suppression of plasminogen activators and the MMP-2/-9 pathway by a Zanthoxylum avicennae extract to inhibit the HA22T human hepatocellular carcinoma cell migration and invasion effects in vitro and in vivo via phosphatase 2A activation. Biosci Biotechnol Biochem (2013) 0.81
CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour Biol (2013) 0.81
Activation of fibroblast collagenase-1 expression by tumor cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2. Cancer Res (2000) 0.79
Protective effect of cyclosporin A on brain injury in rats with acute necrotic pancreatitis. Life Sci (2010) 0.79
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis (2014) 0.79
Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. J Cell Physiol (2014) 0.79
Effects of cyclosporine on metalloproteinase in endothelial cells. Transplant Proc (2012) 0.78
Okadaic acid stimulates nerve growth factor production via an induction of interleukin-1 in primary cultures of cortical astroglial cells. Neurochem Int (1997) 0.77
Peritransplant and long-term secretion of interleukin-1beta in cyclosporine treated syngeneic rats allografted with islets of langerhans. Transplant Proc (2005) 0.77
Okadaic acid induces matrix metalloproteinase-9 expression in fibroblasts: crosstalk between protein phosphatase inhibition and β-adrenoceptor signalling. Br J Pharmacol (2012) 0.77
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential. Oncogene (2016) 0.76